Brief: Kamada, Kedrion Biopharma Announce Results Of U.S. Post-Marketing Pediatric Trial Of A Human Rabies Immune Globulin

Kamada

19/08/2020 12:18

Aug 19 (Reuters) - Kamada Ltd  KMDA.TA :
    * KAMADA AND KEDRION BIOPHARMA ANNOUNCE RESULTS OF FIRST AND
ONLY
U.S. POST-MARKETING PEDIATRIC TRIAL OF A HUMAN RABIES IMMUNE
GLOBULIN (HRIG); THE STUDY MET ITS PRIMARY OBJECTIVE
    * KAMADA LTD - STUDY MET ITS PRIMARY OBJECTIVE, WHICH WAS TO
CONFIRM SAFETY OF KEDRAB IN PEDIATRIC POPULATION
    * KAMADA LTD - STUDY RESULTS HAVE BEEN SUBMITTED TO U.S. FDA
FOR
REVIEW AND POTENTIAL UPDATE TO KEDRAB PRESCRIBING INFORMATION
    * KAMADA LTD -  NO SERIOUS ADVERSE EVENTS WERE OBSERVED
DURING
HRIG STUDY
    * KAMADA LTD -  NO INCIDENCE OF RABIES DISEASE OR DEATHS
WERE
RECORDED THROUGHOUT 84-DAY STUDY PERIOD ON HRIG

Source text for Eikon:  ID:nGNX78b9RV 
Further company coverage:  KMDA.TA 

 ((Reuters.Briefs@thomsonreuters.com;))